Tropisetron and paracetamol association in post-operative patients
Corresponding Author
Gisèle Pickering
CHU Clermont-Ferrand, Centre de Pharmacologie Clinique, F-63003 Clermont-Ferrand, France
Inserm, CIC 501, UMR 766, F-63003 Clermont-Ferrand, France
Laboratoire de Pharmacologie, Faculté de médecine, Clermont Université, F-63001 Clermont-Ferrand, France
Correspondence and reprints: [email protected]Search for more papers by this authorMichael Faure
CHU Clermont-Ferrand, Pôle Anesthésie-Réanimation-SAMU-SMUR, Hôpital Gabriel Montpied, F-63003 Clermont-Ferrand, France
Search for more papers by this authorFabienne Commun
CHU Clermont-Ferrand, Pôle Anesthésie-Réanimation-SAMU-SMUR, Hôpital Gabriel Montpied, F-63003 Clermont-Ferrand, France
Search for more papers by this authorElisabeth Carrier de Boissy
CHU Clermont-Ferrand, Pôle Anesthésie-Réanimation-SAMU-SMUR, Hôpital Gabriel Montpied, F-63003 Clermont-Ferrand, France
Search for more papers by this authorGhislaine Roche
CHU Clermont-Ferrand, Pôle Anesthésie-Réanimation-SAMU-SMUR, Hôpital Gabriel Montpied, F-63003 Clermont-Ferrand, France
Search for more papers by this authorThierry Mom
CHU Clermont-Ferrand, Service d’ORL, F-63003 Clermont-Ferrand, France
Search for more papers by this authorEstelle Simen
CHU Clermont-Ferrand, Centre de Pharmacologie Clinique, F-63003 Clermont-Ferrand, France
Search for more papers by this authorClaude Dubray
CHU Clermont-Ferrand, Centre de Pharmacologie Clinique, F-63003 Clermont-Ferrand, France
Inserm, CIC 501, UMR 766, F-63003 Clermont-Ferrand, France
Laboratoire de Pharmacologie, Faculté de médecine, Clermont Université, F-63001 Clermont-Ferrand, France
Search for more papers by this authorAlain Eschalier
Inserm, CIC 501, UMR 766, F-63003 Clermont-Ferrand, France
Laboratoire de Pharmacologie, Faculté de médecine, Clermont Université, F-63001 Clermont-Ferrand, France
Search for more papers by this authorLaurent Gilain
CHU Clermont-Ferrand, Service d’ORL, F-63003 Clermont-Ferrand, France
Search for more papers by this authorCorresponding Author
Gisèle Pickering
CHU Clermont-Ferrand, Centre de Pharmacologie Clinique, F-63003 Clermont-Ferrand, France
Inserm, CIC 501, UMR 766, F-63003 Clermont-Ferrand, France
Laboratoire de Pharmacologie, Faculté de médecine, Clermont Université, F-63001 Clermont-Ferrand, France
Correspondence and reprints: [email protected]Search for more papers by this authorMichael Faure
CHU Clermont-Ferrand, Pôle Anesthésie-Réanimation-SAMU-SMUR, Hôpital Gabriel Montpied, F-63003 Clermont-Ferrand, France
Search for more papers by this authorFabienne Commun
CHU Clermont-Ferrand, Pôle Anesthésie-Réanimation-SAMU-SMUR, Hôpital Gabriel Montpied, F-63003 Clermont-Ferrand, France
Search for more papers by this authorElisabeth Carrier de Boissy
CHU Clermont-Ferrand, Pôle Anesthésie-Réanimation-SAMU-SMUR, Hôpital Gabriel Montpied, F-63003 Clermont-Ferrand, France
Search for more papers by this authorGhislaine Roche
CHU Clermont-Ferrand, Pôle Anesthésie-Réanimation-SAMU-SMUR, Hôpital Gabriel Montpied, F-63003 Clermont-Ferrand, France
Search for more papers by this authorThierry Mom
CHU Clermont-Ferrand, Service d’ORL, F-63003 Clermont-Ferrand, France
Search for more papers by this authorEstelle Simen
CHU Clermont-Ferrand, Centre de Pharmacologie Clinique, F-63003 Clermont-Ferrand, France
Search for more papers by this authorClaude Dubray
CHU Clermont-Ferrand, Centre de Pharmacologie Clinique, F-63003 Clermont-Ferrand, France
Inserm, CIC 501, UMR 766, F-63003 Clermont-Ferrand, France
Laboratoire de Pharmacologie, Faculté de médecine, Clermont Université, F-63001 Clermont-Ferrand, France
Search for more papers by this authorAlain Eschalier
Inserm, CIC 501, UMR 766, F-63003 Clermont-Ferrand, France
Laboratoire de Pharmacologie, Faculté de médecine, Clermont Université, F-63001 Clermont-Ferrand, France
Search for more papers by this authorLaurent Gilain
CHU Clermont-Ferrand, Service d’ORL, F-63003 Clermont-Ferrand, France
Search for more papers by this authorAbstract
Studies in animals and in healthy volunteers have demonstrated the central serotonergic analgesic mechanism of action of paracetamol involving the inhibition of this analgesia by tropisetron, a 5-HT3 antagonist. This randomized, double-blind, controlled study aims at studying this interaction in post-operative patients after ear surgery. Thirty-six patients are included in two parallel groups with intravenous paracetamol (1 g) and either tropisetron (T, 5 mg/mL) or placebo (c, NaCl 0.9%) administered at the end of surgery. Numerical pain evaluations are performed every 30 min, six times after awakening. The difference between the sums of numerical scales of both groups [9 ± 10 (T) vs. 6 ± 7 (c)] is not significant, but the tropisetron group displays higher pain scores despite additional rescue analgesia. The limits of this trial call for a much larger study to investigate further this pharmacodynamic interaction.
References
- 1 Mallet C., Daulhac L., Bonnefont J. et al. Endocannabinoid and serotonergic systems are needed for paracetamol-induced analgesia. Pain (2008) 139 190–200.
- 2 Tjolsen A., Lund A., Hole K. Antinociceptive effect of paracetamol in rats is partly dependent on spinal serotonergic systems. Eur. J. Pharmacol. (1991) 193 193–201.
- 3 Alloui A., Pelissier T., Dubray C., Lavarenne J., Eschalier A. Tropisetron inhibits the antinociceptive effect of intrathecally administered paracetamol and serotonin. Fundam. Clin. Pharmacol. (1996) 10 406–407.
- 4 Pelissier T., Alloui A., Caussade F. et al. Paracetamol exerts a spinal antinociceptive effect involving an indirect interaction with 5 hydroxytryptamine3 receptors: in vivo and in vitro evidence. J. Pharmacol. Exp. Ther. (1996) 278 8–14.
- 5 Bonnefont J., Chapuy E., Clottes E., Alloui A., Eschalier A. Spinal 5-HT1A receptors differentially influence nociceptive processing according to the nature of the noxious stimulus in rats: effect of WAY-100635 on the antinociceptive activities of paracetamol, venlafaxine and 5-HT. Pain (2005) 114 482–490.
- 6 Libert F., Bonnefont J., Bourinet E. et al. Paracetamol: a central analgesic drug that involves a spinal tropisetron-sensitive, non–5-HT3 receptor-mediated effect. Mol. Pharmacol. (2004) 66 728–733.
- 7 Pickering G., Loriot M.A., Libert F., Eschalier A., Beaune P., Dubray C. Analgesic effect of paracetamol in humans: first evidence of a central serotonergic mechanism. Clin. Pharmacol. Ther. (2006) 79 371–378.
- 8 Bonnefont J., Alloui A., Chapuy E., Clottes E., Eschalier A. Orally administered paracetamol does not act locally in the rat formalin test: evidence for a supraspinal, serotonin-dependent antinociceptive mechanism. Anesthesiology (2003) 99 976–981.
- 9 Pini L.A., Sandrini M., Vitale G. The antinociceptive action of paracetamol is associated with changes in the serotonergic system in the rat brain. Eur. J. Pharmacol. (1996) 308 31–40.
- 10 Pickering G., Estève V., Loriot M.A., Eschalier A., Dubray C. Acetaminophen reinforces descending inhibitory pain pathways. Clin. Pharmacol. Ther. (2008) 84 47–51.
- 11
Ventafridda V.,
Tamburini M.,
Caraceni A.,
De Conno F.,
Naldi F.
A validation study of the WHO method for cancer pain relief.
Cancer (1987) 59
850–856.
10.1002/1097-0142(19870215)59:4<850::AID-CNCR2820590432>3.0.CO;2-1 CAS PubMed Web of Science® Google Scholar
- 12 Jokela R., Ahonen J., Seitsonen E., Marjakangas P., Korttila K. The influence of ondansetron on the analgesic effect of acetaminophen after laparoscopic hysterectomy. Clin. Pharmacol. Ther. (2010) 87 672–678.
- 13 Langlois A., Pascaud X., Junien J.L., Dahl S.G., Riviere P.J. Response heterogeneity of 5-HT3 receptor antagonists in a rat visceral hypersensitivity model. Eur. J. Pharmacol. (1996) 318 141–144.
- 14 Girard P., Pansart Y., Coppé M.C., Niedergang B., Gillardin J.M. Modulation of paracetamol and nefopam antinociception by serotonin 5-HT(3) receptor antagonists in mice. Pharmacology (2009) 83 243–246.
- 15 Hunskaar S., Hole K. The formalin test in mice: dissociation between inflammatory and non-inflammatory pain. Pain (1987) 30 103–114.
- 16 Arranz B., Rosel P., San L., Sarro S., Navarro M.A., Marcusson J. Characterization of the 5-HT4 binding site in human brain. J. Neural. Transm. (1998) 105 575–586.
- 17 Rothlin C.V., Katz E., Verbitsky M., Elgoyhen A.B. The α9 nicotinic acetylcholine receptor shares pharmacological properties with type A γ-aminobutyric acid, glycine and type 3 serotonin receptors. Mol. Pharmacol. (1999) 55 248–254.
- 18 Macor J.E., Gurley D., Lanthorn T. et al. The 5-HT3 antagonist tropisetron (ICS 205–930) is a potent and selective alpha7 nicotinic receptor partial agonist. Bioorg. Med. Chem. Lett. (2001) 11 319–321.
- 19 Maksay G., Laube B., Betz H. Selective blocking effects of tropisetron and atropine on recombinant glycine receptors. J. Neurochem. (1999) 73 802–806.
- 20 Blower P.R. 5-HT3-receptor antagonists and the cytochrome P450 system: clinical implications. Cancer J. (2002) 8 405–414.
Citing Literature
